Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Antisense oligonucleotide for severe hypertriglyceridemia
Reduced Incidence of Acute Pancreatitis
- Hereditary Transthyretin Amyloidosis with Polyneuropathy
New Treatment Options for ATTRv-PN
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach
Slowing the loss of β-cell function and delaying the progression of the disease
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain
Implementing a biopsychosocial approach
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome